Market Newsdesk

LOS ANGELES, Jan. 3, 2022 /PRNewswire/ — LiveOne (Nasdaq: LVO), a global platform for livestream and on-demand audio, video, and podcast/vodcast content in music, comedy, and pop culture, and owner of LiveXLive, PodcastOne, Slacker Radio, React Presents, Gramophone Media, Palm Beach Records and Custom Personalization Solutions, announced today that approximately $2.4 million of outstanding debt was exchanged into shares of LiveOne’s common stock at a price of $2.10 per share. LiveOne expects holders of substantial additional payables and debt to also convert/exchange into LiveOne’s equity.

LiveOne has the first talent-centric platform focused on superfans and building long-term franchises in on-demand audio and video, podcasting, vodcasting, OTT linear channels, pay-per-view, NFTs, and livestreaming. Its unique model includes multiple monetization paths including subscription, advertising, sponsorship, merchandise sales, licensing, and ticketing.

About LiveOne, Inc.

Headquartered in Los Angeles, California, LiveOne, Inc. (NASDAQ: LVO) (the “Company”) is a global talent-first, interactive music, sports, and entertainment subscription platform delivering premium content and livestreams from the world’s top artists. The Company has streamed over 1,800 artists since January 2020, a library featuring close to 30 million songs, 500 expertly curated radio stations, 235 podcasts/vodcasts, hundreds of pay-per-views, personalized merchandise, and NFTs business, and has created a valuable connection between brands, fans, and bands. The Company’s other major wholly-owned subsidiaries are LiveXLive, PPVOne, Slacker Radio, React Presents, Gramophone Media, Palm Beach Records, Custom Personalization Solutions, and PodcastOne, which generates more than 2.48 billion downloads per year and 300+ episodes distributed per week across a stable of hundreds of top podcasts. The combination of acquisitions and the expansion of products and franchises have secured LiveOne as a top-rated music, entertainment, and media services company. LiveXLive is available on iOS, Android, Roku, Apple TV, and Amazon Fire, and through OTT, STIRR, Sling, and XUMO, in addition to its app, online website, and social channels. For more information, visit www.livexlive.com and follow us on Facebook, Instagram, TikTok, and Twitter at @livexlive.

*About Non-GAAP Financial Measures

To supplement our consolidated financial statements, which are prepared and presented in accordance with the accounting principles generally accepted in the United States of America (“GAAP”), we present Contribution Margin (Loss) and Adjusted Earnings Before Interest Tax Depreciation and Amortization (“Adjusted EBITDA”), which are non-GAAP financial measures, as measures of our performance. The presentation of these non-GAAP financial measures is not intended to be considered in isolation from, or as a substitute for, or superior to, operating loss and or net income (loss) or any other performance measures derived in accordance with GAAP or as an alternative to net cash provided by operating activities or any other measures of our cash flows or liquidity.

We use Contribution Margin (Loss) and Adjusted EBITDA to evaluate the performance of our operating segment. We believe that information about these non-GAAP financial measures assists investors by allowing them to evaluate changes in the operating results of our business separate from non-operational factors that affect operating income (loss) and net income (loss), thus providing insights into both operations and the other factors that affect reported results. Adjusted EBITDA is not calculated or presented in accordance with GAAP. A limitation of the use of Adjusted EBITDA as a performance measure is that it does not reflect the periodic costs of certain amortizing assets used in generating revenue in our business. Accordingly, Adjusted EBITDA should be considered in addition to, and not as a substitute for, operating income (loss), net income (loss), and other measures of financial performance reported in accordance with GAAP. Furthermore, this measure may vary among other companies; thus, Adjusted EBITDA as presented herein may not be comparable to similarly titled measures of other companies.

Contribution Margin (Loss) is defined as Revenue less Cost of Sales. Adjusted EBITDA is defined as earnings before interest, other (income) expense, income tax expense, depreciation and amortization and before (a) non-cash GAAP purchase accounting adjustments for certain deferred revenue and costs, (b) legal, accounting and other professional fees directly attributable to acquisition activity, (c) employee severance payments and third party professional fees directly attributable to acquisition or corporate realignment activities, (d) certain non-recurring expenses associated with legal settlements or reserves for legal settlements in the period that pertain to historical matters that existed at acquired companies prior to their purchase date and a one-time minimum guarantee to effectively terminate a live events distribution agreement post COVID-19, (e) depreciation and amortization (including goodwill impairment, if any), and (f) certain stock-based compensation expense.  Management does not consider these costs to be indicative of our core operating results.

With respect to projected full fiscal year 2022 and 2023 Adjusted EBITDA, a quantitative reconciliation is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to purchase accounting adjustments, acquisition-related charges and legal settlement reserves excluded from Adjusted EBITDA. We expect that the variability of these items to have a potentially unpredictable, and potentially significant, impact on our future GAAP financial results.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are “forward-looking statements,” which may often, but not always, be identified by the use of such words as “may,” “might,” “will,” “will likely result,” “would,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “no target” or the negative of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including: the Company’s reliance on one key customer for a substantial percentage of its revenue; the Company’s ability to consummate any proposed financing, acquisition, spin-out, distribution or transaction, the timing of the closing of such proposed event, including the risks that a condition to closing would not be satisfied within the expected timeframe or at all, or that the closing of any proposed financing, acquisition, spin-out, distribution or transaction will not occur or whether any such event will enhance shareholder value; the Company’s ability to continue as a going concern; the Company’s ability to attract, maintain and increase the number of its users and paid subscribers; the Company identifying, acquiring, securing and developing content; the Company’s intent to repurchase shares of its common stock from time to time under its announced stock repurchase program and the timing, price, and quantity of repurchases, if any, under the program; the Company’s ability to maintain compliance with certain financial and other covenants; the Company successfully implementing its growth strategy, including relating to its technology platforms and applications; management’s relationships with industry stakeholders; the effects of the global Covid-19 pandemic; changes in economic conditions; competition; risks and uncertainties applicable to the businesses of the Company’s subsidiaries; and other risks, uncertainties and factors including, but not limited to, those described in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2021, filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 14, 2021, the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2021, filed with the SEC on August 16, 2021, the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2021, filed with the SEC on October 29, 2021, and in the Company’s other filings and submissions with the SEC. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligations to update these statements, except as may be required by law. The Company intends that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. 

LiveOne IR Contact: 
310.601.2505
[email protected]

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/liveone-continues-its-efforts-to-consolidate-and-restructure-react-presents-live-business-to-build-momentum-with-2-4-million-of-outstanding-short-term-debt-exchanged-at-2-10-per-share-301452574.html

SOURCE LiveOne, Inc.

LOS ANGELES, Jan. 3, 2022 /PRNewswire/ — Rexford Industrial Realty, Inc. (the “Company” or “Rexford Industrial”) (NYSE: REXR), a real estate investment trust focused on creating value by investing in and operating industrial properties located in Southern California infill markets, today announced the acquisition of eight industrial properties for an aggregate purchase price of $270 million. The acquisitions were funded using cash on hand and proceeds from forward equity settlements. For the full year 2021, the Company acquired $1.9 billion of industrial properties, bringing the Company’s total portfolio to 296 properties comprising approximately 37.1 million square feet within prime infill Southern California “last-mile” submarkets.

“These eight investments, acquired through off-market and lightly marketed transactions, deliver substantial value creation and result from Rexford’s deep, local sharp-shooter market knowledge and relationships, our value-add expertise and proprietary access to the infill Southern California market, the nation’s strongest, highest demand and highest-barrier industrial property market,” stated Howard Schwimmer and Michael Frankel, Co-Chief Executive Officers of the Company. “Our $1.9 billion of investments completed in 2021 are indicative of Rexford’s substantial go-forward growth opportunity, given the unique position we hold in the world’s fourth largest industrial market, which surpasses in size all global markets except the entire national markets of the United States, China and Germany. With over $400 million of additional investments under contract or accepted offer, plus a broad range of internal growth initiatives under-way, our low-leverage, fortress-like balance sheet supports the expansion of our best-in-class portfolio and our ability to generate above-market cash flow growth and long-term value creation for our stakeholders.”

In December, through off-market and lightly marketed transactions, the Company acquired:

• A property located in the western portion of the City of Industry, CA, within the LA – San Gabriel Valley submarket for $28.6 million, or $86 per land square foot. The 7.6-acre site contains a single tenant 111,927 square foot building acquired through a multi-year sale-leaseback. Upon lease expiration, the Company intends to execute a redevelopment of the site. The initial 3.5% unlevered cash yield is projected to grow to a stabilized unlevered cash yield on total investment of approximately 5.0%. According to CBRE, the vacancy rate in the 159 million square-foot San Gabriel Valley submarket was 0.2% at the end of the third quarter 2021.
• 2391-2393 Bateman Avenue, located in Irwindale, within the LA – San Gabriel Valley submarket for $23.1 million, or $352 per square foot. The 65,605 square foot, single tenant Class-A industrial facility is situated on 3.4 acres of land. The property is subject to a long-term sale leaseback with an initial unlevered cash yield on total investment of 4.0%, with contractual 3.0% annual rent increases through the lease term.
• 1020 Bixby Drive, located in the City of Industry, within the LA – San Gabriel Valley submarket for $16.4 million, or $287 per square foot. The 56,915 square foot warehouse building is fully leased at a rental rate estimated to be approximately 30% below market rates. Upon lease expiration, the Company intends to drive cash flow growth through either value-add repositioning and re-tenanting or through lease renewal at market rent. The initial 3.6% unlevered cash yield is projected to grow to a stabilized unlevered cash yield on total investment of 4.5%.
• 2800 Casitas Avenue, located in Los Angeles, within the LA – Greater San Fernando Valley submarket for $43.0 million, or $368 per square foot. The 5.7-acre site contains a 117,000 square foot, two-tenant industrial building leased at rental rates estimated to be approximately 60% below market rates. Upon near-term lease expiration, the Company intends to perform value-add repositioning, upgrading the building to a state-of-the-art last-mile warehouse/distribution facility. The investment is projected to generate a 4.5% stabilized unlevered cash yield on total investment. According to CBRE, the vacancy rate in the 180 million square-foot Greater San Fernando Valley submarket was 1.1% at the end of the third quarter 2021.
• 4240 W. 190^th Street, located in Torrance, within the LA – South Bay submarket for $75.3 million, or $149 per land square foot. The fully leased, 307,000 square foot, two-tenant industrial building is currently leased at rental rates estimated to be 40% below market rates. Upon lease expiration, the Company plans to redevelop the 11.6-acre site into a best-in-class, single-tenant logistics facility. The initial 3.0% unlevered cash yield is projected to grow to a stabilized unlevered cash yield on total investment of 5.1%. According to CBRE, the vacancy rate in the 218 million square-foot LA – South Bay submarket was 0.6% at the end of the third quarter 2021.
• 8911 Aviation Boulevard, located in Inglewood, within the LA – South Bay submarket for $32.0 million, or $183 per land square foot. The 4.0-acre covered land site contains 100,000 square feet of buildings, leased to a single tenant located immediately adjacent to the Los Angeles International Airport. Following the expiration of the current long-term lease, the Company intends to redevelop the site by constructing two new, best-in-class logistics buildings. The initial unlevered cash yield is 4.7%.
• 3071 E. Coronado Street, located in Anaheim, within the Orange County – North submarket for $28.0 million, or $131 per land square foot. The 4.9-acre land site will be immediately redeveloped by constructing a new 106,925 square foot building featuring 36′ clear height. Upon lease-up, the investment is projected to generate a 4.7% stabilized unlevered cash yield on total investment. According to CBRE, the vacancy rate in the 115 million square-foot Orange County – North submarket was 0.9% at the end of the third quarter 2021. 
• 1168 Sherborn Boulevard, located in Corona, within the Inland Empire – West submarket for $23.4 million, or approximately $295 per square foot. The 79,515 square foot building was acquired in a long-term sale-leaseback transaction with in-place rent estimated to be 25% below market rates. The initial 3.5% unlevered cash yield is projected to grow over time driven by contractual 3.75% annual rent escalations. According to CBRE, the vacancy rate in the 319 million square-foot Inland Empire – West submarket was 0.8% at the end of the third quarter 2021. 

About Rexford Industrial

Rexford Industrial, a real estate investment trust focused on creating value by investing in and operating industrial properties throughout Southern California infill markets, owns 296 properties with approximately 37.1 million rentable square feet and manages an additional 20 properties with approximately 1.0 million rentable square feet. For additional information, visit www.rexfordindustrial.com.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the federal securities laws, which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” or “potential” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. While forward-looking statements reflect the Company’s good faith beliefs, assumptions and expectations, they are not guarantees of future performance. For a further discussion of these and other factors that could cause the Company’s future results to differ materially from any forward-looking statements, see the reports and other filings by the Company with the U.S. Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and the Company’s most recent Form 10-Q. The Company disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes.

Contact:
Investor Relations:
Stephen Swett
424 256 2153 ext. 401
[email protected]

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/rexford-industrial-acquires-eight-properties-for-270-million—full-year-2021-acquisitions-total-1-9-billion-301452558.html

SOURCE Rexford Industrial Realty, Inc.

LAS VEGAS, Jan. 3, 2022 /PRNewswire/ — Consumer Electronics Show – CEVA, Inc. (NASDAQ: CEVA), the leading licensor of wireless connectivity and smart sensing technologies and integrated IP solutions, and ASPEED Technology, have announced that ASPEED has licensed and deployed the CEVA-BX1 audio/voice DSP in its 2^nd generation Cupola360 SoC, AST1230 for smart cameras and video conferencing systems. The companies are also collaborating to address the most challenging conferencing use cases with the availability of CEVA’s ClearVox multi-microphone noise reduction & acoustic echo cancellation audio front end (AFE) software. This software package is fully optimized for the CEVA-BX1 DSP, significantly enhancing the intelligibility of any voice conferencing system and allowing voice assistants and hands-free control capabilities to be added.

Chris Lin, Chairman and President of ASPEED Technology, commented: “Our 2^nd generation Cupola360 SoC is our first product to incorporate real-time multi-image stitching video and powerful audio processing capabilities, making it perfect for video conferencing applications. Through the comprehensive cooperation between CEVA and ASPEED, our customers can enjoy the most superior video & audio functionality and we are glad to have CEVA as our strong and trusted partner.”

ASPEED’s 2^nd generation Cupola360 multi-image stitching video & audio SoC, AST1230, as well as the accompanying app, is specifically designed for high performance video conferencing applications. With a focus on advanced smart cameras for spherical video conferencing applications, the AST1230 SoC features include a powerful image signal processor (ISP) and a smart layout processing engine. Incorporating ASPEED’s unique Hyper-stitching® technology, the AST1230 SoC is engineered to deliver extraordinary processing power for on-device real-time image stitching. Incorporating the high level programmable CEVA-BX1 DSP to tackle the most challenging audio/voice use cases, the AST1230 SoC offers exceptional power and thermal efficiency, making it ideal for a wide range of emerging IoT applications. Additional features include 8 digital MIC inputs with powerful audio processing algorithms, including far-field speech, beam-forming, auto gain control (AGC), noise suppression, and echo cancelation.

Moshe Sheier, Vice President of Marketing at CEVA, added: “Video conferencing plays an increasingly critical role in most organizations and work-from-home scenarios today, and their underlying equipment is key to making the experience effortless and productive. We’re pleased to partner with ASPEED, one of the leaders in this space, to ensure that the voice experience of these systems is seamless and powerful, no matter the user environment. Our value-add ClearVox voice software illustrates the unique value we can bring to our customers with our hardware + software approach to IP, and we look forward to collaborating with ASPEED and their customers to introduce a new generation of smart conferencing systems to the market.”

The CEVA-BX1 processor combines efficient DSP compute capability with high-level programming and compact code size requirements of embedded applications. Using an 11-stage pipeline and 4-way VLIW micro-architecture, it offers parallel processing with a Single Instruction Multiple Data (SIMD) ISA, widely used in neural networks inference, noise reduction and echo cancellation, as well as high accuracy sensor fusion algorithms. The CEVA-BX1 is accompanied by a comprehensive software development tool chain, including an advanced LLVM compiler, Eclipse based debugger, DSP and neural network compute libraries, neural network frameworks support in the form of Tensorflow Lite Micro, and choice of industry leading Real Time Operating Systems (RTOS). For more information, visit https://www.ceva-dsp.com/product/ceva-bx1-sound/.

Developed in-house and leveraging CEVA’s vast expertize in audio and voice processing, ClearVox audio front end incorporates advanced algorithms that cope with different acoustic scenarios and microphone configurations, including optimized software for speaker direction of arrival, multi-mic beamforming, noise suppression and acoustic echo cancellation, as well as the related firmware and driver software. For more information, visit https://www.ceva-dsp.com/product/ceva-clearvox/.

About ASPEED Technology Inc.
ASPEED Technology Inc. is a leading fabless IC design company and a top pioneer of SoC (System on Chip) solutions. As the world’s largest BMC SoC supplier, ASPEED Technology is devoted to developing proprietary innovative technologies that quickly respond to customer needs. ASPEED Technology’s R&D areas include BMC (Baseboard Management Controller SoC), PC/AV Extension SoC. In 2017, we officially released the Cupola360 Multi-Image Stitching Processing SoC – an image processor specifically designed for multiple images stitching technology, as well as the accompanying mobile apps. Applications include videoconferencing and spherical live streaming camera, which expanded our product lines into images and graphics. Forbes included ASPEED Technology on its Asia’s 200 Best Under a Billion list for three consecutive years from 2018 to 2020 after previously naming us to the list in 2014 and 2015, underscoring how we are a partner worthy of our customers’ confidence. In 2016, ASPEED Technology announced the acquisition of Broadcom’s Emulex Pilot™ BMC SoC business and is currently the world’s No. 1 BMC (Baseboard Management Controller) chipset provider. For more detailed information, please visit ASPEED website at www.aspeedtech.com and Cupola360.com.

About CEVA, Inc.
CEVA is the leading licensor of wireless connectivity and smart sensing technologies and integrated IP solutions for a smarter, safer, connected world. We provide Digital Signal Processors, AI engines, wireless platforms, cryptography cores and complementary software for sensor fusion, image enhancement, computer vision, voice input and artificial intelligence. These technologies are offered in combination with our Intrinsix IP integration services, helping our customers address their most complex and time-critical integrated circuit design projects. Leveraging our technologies and chip design skills, many of the world’s leading semiconductors, system companies and OEMs create power-efficient, intelligent, secure and connected devices for a range of end markets, including mobile, consumer, automotive, robotics, industrial, aerospace & defense and IoT.

Our DSP-based solutions include platforms for 5G baseband processing in mobile, IoT and infrastructure, advanced imaging and computer vision for any camera-enabled device, audio/voice/speech and ultra-low-power always-on/sensing applications for multiple IoT markets. For sensor fusion, our Hillcrest Labs sensor processing technologies provide a broad range of sensor fusion software and inertial measurement unit (“IMU”) solutions for markets including hearables, wearables, AR/VR, PC, robotics, remote controls and IoT. For wireless IoT, our platforms for Bluetooth (low energy and dual mode), Wi-Fi 4/5/6/6e (802.11n/ac/ax), Ultra-wideband (UWB) and NB-IoT are the most broadly licensed connectivity platforms in the industry. 

Visit us at www.ceva-dsp.com and follow us on Twitter, YouTube, Facebook, LinkedIn and Instagram.

https://mma.prnewswire.com/media/74483/ceva__inc__logo.jpg

View original content:https://www.prnewswire.com/news-releases/aspeed-and-ceva-collaborate-to-enable-superior-voice-experience-on-2nd-generation-cupola360-soc-for-smart-cameras-and-video-conferencing-systems-301452557.html

SOURCE CEVA, Inc.

CHARLOTTE, N.C., Jan. 3, 2022  – Gambling.com Group Limited (Nasdaq: GAMB) (“Gambling.com Group” or the “Group”), a leading provider of player acquisition services for the regulated global online gambling industry, today announced the successful completion of its planned acquisition of Roto Sports, Inc. (“Roto Sports”), operator of RotoWire.com (“RotoWire”), a popular provider of expert fantasy sports news and advice.

“We completed the acquisition according to our internal timelines on January 1^st, 2022 and thank the RotoWire team for their professionalism and availability through the holiday period. We will consolidate Roto Sports into our Group Financial Statements from January 1^st, 2022,” said Elias Mark, Chief Financial Officer at Gambling.com Group.

Additional information about the acquisition can be found here.

For further information, please contact:

Media:
Derek Brookmeyer, Gambling.com Group, [email protected], 616-528-0882 
Investors: Ross Collins, Alpha-IR Group, [email protected], 312-445-2877

About Gambling.com Group
Gambling.com Group Limited (Nasdaq: GAMB) is a multi-award-winning performance marketing company and a leading provider of digital marketing services active exclusively in the online gambling industry. The Group operates from offices in Ireland, the United States, and Malta. Through its proprietary technology platform, the Group publishes a portfolio of premier branded websites including Gambling.com and Bookies.com. Founded in 2006, the Group owns and operates more than 30 websites in six languages across 13 national markets covering all aspects of the online gambling industry, which includes iGaming and sports betting.

View original content to download multimedia:https://www.prnewswire.com/news-releases/gamblingcom-group-completes-acquisition-of-rotowire-301452504.html

SOURCE Gambling.com Group

JERUSALEM, Jan. 3, 2022 /PRNewswire/ — Alpha Tau Medical Ltd. (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has been notified by HekaBio K.K., its clinical trial partner in Japan, that recruitment has been completed in its open-label multi-center pivotal study evaluating the Alpha DaRT in Japanese patients with recurrent Head & Neck cancer after radiotherapy.

HekaBio has reported that preliminary results of this trial are highly encouraging, and that it will continue compilation and analysis of the data in collaboration with its medical experts, in an effort to prepare a submission seeking marketing approval via the shonin pathway in consultation with Japanese authorities. No results of the clinical trial are expected to be published until submission to the Japanese authorities.

Alpha Tau CEO Uzi Sofer remarked, “This is an important milestone for Alpha Tau, as we look to bring our unique Alpha DaRT therapy to patients around the world. Having secured our first marketing authorization in Israel, we look forward to seeing pivotal trial data from Japan, with an eye toward initiating a pivotal trial in the U.S. in 2022. Japan is an important market for Alpha Tau, and we appreciate the untiring efforts of HekaBio CEO Rob Claar and his team, as well as all of the investigators from leading cancer centers in Japan who have participated in this trial.”

About Alpha DaRT

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the source and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

About Alpha Tau Medical Ltd.

Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

On July 8, 2021, Alpha Tau announced that it had entered into a definitive merger agreement (the “Merger Agreement”) with Healthcare Capital Corp. (Nasdaq: HCCC) (“HCCC”), a special purpose acquisition company, pursuant to which Alpha Tau would consummate a business combination transaction (the “Business Combination”) with HCCC and become a Nasdaq-listed public company.

Media Package: https://www.alphatau.com/media-package

Additional Information and Where to Find It

For additional information on the Business Combination, see HCCC’s Current Report on Form 8-K, which was filed with the Securities and Exchange Commission (“SEC”) on July 8, 2021.

In connection with the proposed transaction with HCCC, Alpha Tau has filed a Registration Statement on Form F-4, which includes a preliminary proxy statement/prospectus of HCCC.

Investors and security holders of HCCC are advised to read, when available, the preliminary proxy statement, and amendments thereto, and the definitive proxy statement in connection with HCCC’s solicitation of proxies for its special meeting of stockholders to be held to approve the proposed Business Combination because the proxy statement/prospectus will contain important information about the proposed transaction and the parties to the proposed transaction. The definitive proxy statement/prospectus will be mailed to stockholders of HCCC as of a record date to be established for voting on the proposed Business Combination.

Stockholders will also be able to obtain copies of the Registration Statement, proxy statement/prospectus, and Form 8-K, without charge at the SEC’s website at www.sec.gov.

No Offer or Solicitation

This announcement is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed Business Combination or otherwise, nor shall there be any sale, issuance or transfer or securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Participants in the Solicitation

HCCC and Alpha Tau and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of HCCC’s stockholders in connection with the proposed Business Combination between HCCC and Alpha Tau. Investors and security holders may obtain more detailed information regarding the names and interests in the proposed transaction of HCCC’s directors and officers HCCC’s and Alpha Tau’s filings with the SEC, including the Registration Statement.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including “anticipate,” “being,” “will,” “plan,” “may,” “continue,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Alpha Tau’s and HCCC’s current expectations and various assumptions. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) Alpha Tau’s ability to receive regulatory approval for its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau’s limited operating history; (iii) Alpha Tau’s incurrence of significant losses to date; (iv) Alpha Tau’s need for additional funding and ability to raise capital when needed; (v) Alpha Tau’s limited experience in medical device discovery and development; (vi) Alpha Tau’s dependence on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau’s clinical studies to predict final study results; (viii) failure of Alpha Tau’s early clinical studies or preclinical studies to predict future clinical studies; (ix) Alpha Tau’s ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau’s Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau’s exposure to patent infringement lawsuits; (xii) Alpha Tau’s ability to comply with the extensive regulations applicable to it; (xiii) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement and the proposed Merger contemplated thereby; (xiv) the inability to complete the transactions contemplated by the Merger Agreement due to the failure to obtain approval of the stockholders of HCCC or other conditions to closing in the Merger Agreement; (xv) the inability to meet the aggregate transaction proceeds requirements of the Merger Agreement due to the inability to consummate the PIPE Investment or the amount of cash available following any redemptions by HCCC’s stockholders; (xvi) the ability to meet Nasdaq’s listing standards following the consummation of the transactions contemplated by the Merger Agreement; (xvii) the risk that the proposed transactions disrupt current plans and operations of Alpha Tau as a result of the announcement and consummation of the transaction described herein; (xviii) the ability to recognize the anticipated benefits of the proposed Merger, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (xix) costs related to the proposed Merger; (xx) changes in applicable laws or regulations; (xxi) impacts from the COVID-19 pandemic; and the other important factors discussed under the caption “Risk Factors” in Alpha Tau’s Registration Statement on Form F-4 originally filed with the SEC on August 19, 2021, as amended, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing Alpha Tau’s views as of any date subsequent to the date of this press release.

Logo – https://mma.prnewswire.com/media/733268/Alpha_Tau_Medical_Logo.jpg

Contact:

Amnon Gat
+972-54-9746276 
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/alpha-tau-announces-completion-of-enrollment-of-japanese-pivotal-clinical-trial-in-recurrent-head–neck-cancer-301452566.html

SOURCE Alpha Tau Medical

ST. LOUIS, Jan. 3, 2022 /PRNewswire/ — Arch Resources, Inc. (NYSE: ARCH) today announced that Molly P. Zhang (aka Peifang Zhang) has been elected to its board of directors, effective immediately.

“We are excited to have Molly join the Arch Resources board,” said John W. Eaves, Arch’s board chair.  “She brings exceptional leadership skills, tremendous global business and technical expertise, and a wealth of board-related experience in the industrial, energy and environmental services sectors.  I am certain she will be a great addition to the Arch team.” 

“I share John’s enthusiasm in welcoming Molly to the Arch team and know that she will be an excellent fit with our already high-performing board,” said Paul A. Lang, Arch’s CEO and president.  “I look forward to working with Molly and the rest of the board as we continue to chart Arch’s future course in a smart, responsible and value-creating manner.”

Zhang brings three decades of international leadership experience in the areas of global operations, business, and technology.  She previously served in various global executive roles for Orica Limited, a global mining services company, most recently as vice president of asset management.  Prior to that time, she held diverse senior leadership positions for Dow Inc., including managing director of SCG-Dow Group; global business vice president for Dow’s Technology Licensing and Catalyst business; and manufacturing director for Dow Asia Pacific.  

Zhang currently serves as a corporate director of Gates Industrial Corporation plc and Aqua Metals, Inc., as well as on several private company boards. Her previous public board experience includes GEA Group, Cooper-Standard Holdings, Inc. and Newmont Mining Corporation.  She holds a master’s degree in Chemistry and a PhD in Chemical Engineering at the Technical University of Clausthal, Germany.

Arch Resources is a premier producer of high-quality metallurgical products for the global steel industry.  The company operates large, modern and highly efficient mines that consistently set the industry standard for both mine safety and environmental stewardship.  Arch Resources from time to time utilizes its website – www.archrsc.com – as a channel of distribution for material company information.  To learn more about us and our premium metallurgical products, go to www.archrsc.com.

Forward-Looking Statements: This press release contains “forward-looking statements” – that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance, and often contain words such as “should,” “appears,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. For us, particular uncertainties arise from the COVID-19 pandemic, including its adverse effects on businesses, economies, and financial markets worldwide; from the impact of COVID-19 on efficiency, costs and production; from changes in the demand for our coal by the steel production and electricity generation industries; from our ability to access the capital markets on acceptable terms and conditions; from policy, legislation and regulations relating to the Clean Air Act, greenhouse gas emissions, incentives for alternative energy sources, and other environmental initiatives; from competition within our industry and with producers of competing energy sources; from our ability to successfully acquire or develop coal reserves, including the integration of our Leer South mine and its ramp-up to full production; from operational, geological, permit, labor, transportation, and weather-related factors; from the effects of foreign and domestic trade policies, actions or disputes; from fluctuations in the amount of cash we generate from operations, which could impact, among other things, our ability to service our outstanding indebtedness, fund capital expenditures, and pay dividends in accordance with our announced plan; from our ability to successfully integrate the operations that we acquire; from our ability to generate significant revenue to make payments required by, and to comply with restrictions related to, our indebtedness, including our ability to repurchase our convertible notes; from additional demands for credit support by third parties; from the loss of, or significant reduction in, purchases by our largest customers; from the development of future technology to replace coal with hydrogen in the steelmaking process; and from numerous other matters of national, regional and global scale, including those of a political, economic, business, competitive or regulatory nature. These uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. For a description of some of the risks and uncertainties that may affect our future results, you should see the risk factors described from time to time in the reports we file with the Securities and Exchange Commission.

View original content to download multimedia:https://www.prnewswire.com/news-releases/molly-p-zhang-elected-to-archs-board-of-directors-301452151.html

SOURCE Arch Resources, Inc.

CAMBRIDGE, Mass., Jan. 3, 2022 /PRNewswire/ — Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the 40^th Annual J.P. Morgan Healthcare Conference. The conference will be held in a virtual meeting format.

Leap Presentation Details:

40^th Annual J.P. Morgan Healthcare Conference
Date: Thursday, January 13
Time: 9:00 a.m. Eastern Time

The presentation will be webcast live and may be accessed on the Investors page of the company’s website at https://investors.leaptx.com/, where a replay of the event will also be available for a limited time.

About Leap Therapeutics

Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap’s most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. For more information about Leap Therapeutics,visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements include Leap’s expectations with respect to the development and advancement of DKN-01, including the initiation, timing and design of future studies, enrollment in future studies, potential for the receipt of future option exercise, milestone, or royalty payments from BeiGene, and other future expectations, plans and prospects. Although Leap believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from our expectations. Such risks and uncertainties include, but are not limited to: that the initiation, conduct, and completion of clinical trials, laboratory operations, manufacturing campaigns, and other studies may be delayed, adversely affected, or impacted by COVID-19 related issues; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; the size and growth potential of the markets for our drug product candidates; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially will be included in Leap Therapeutics’ periodic filings with the SEC, including Leap’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed with the SEC on March 12, 2021 and as may be updated by Leap’s Quarterly Reports on Form 10-Q and the other reports Leap files from time to time with the SEC. Any forward-looking statement contained in this release speaks only as of its date. Leap undertakes no obligation to update any forward-looking statement contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

CONTACT:

Douglas E. Onsi

President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
[email protected]

Matthew DeYoung

Investor Relations
Argot Partners
212-600-1902
[email protected]

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/leap-therapeutics-to-present-at-40th-annual-jp-morgan-healthcare-conference-301451712.html

SOURCE Leap Therapeutics, Inc.

LEXINGTON, Mass., Jan. 3, 2022 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the H.C. Wainwright BioConnect Conference. The presentation will be available for on-demand viewing starting on Monday, January 10, 2022 at 7:00 a.m. ET.

A live webcast of the presentation will be available under “Events & Presentations” in the Investors section of the Company’s website at www.curis.com. A replay of the webcast will be available on the Curis website for 90 days following the event.

About Curis, Inc.

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1/2 trial in patients with non-Hodgkin lymphoma both as a monotherapy and in combination with BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a Phase 1/2 trial in patients with acute myeloid leukemia and myelodysplastic syndromes, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1 trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis’ website at www.curis.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-present-at-hc-wainwright-bioconnect-conference-301452433.html

SOURCE Curis, Inc.

MINNEAPOLIS, Jan. 3, 2022 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 40^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 4:30 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne’s Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions – notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne’s product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne’s genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx^® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne’s Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $931 million in net sales in fiscal 2021 and has approximately 2,700 employees worldwide.

Contact:  David Clair, Senior Director, Investor Relations & Corporate Development
               [email protected]
               612-656-4416

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-jp-morgan-healthcare-conference-301451016.html

SOURCE Bio-Techne Corporation